JP2025514978A5 - - Google Patents

Info

Publication number
JP2025514978A5
JP2025514978A5 JP2024563648A JP2024563648A JP2025514978A5 JP 2025514978 A5 JP2025514978 A5 JP 2025514978A5 JP 2024563648 A JP2024563648 A JP 2024563648A JP 2024563648 A JP2024563648 A JP 2024563648A JP 2025514978 A5 JP2025514978 A5 JP 2025514978A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
acid sequence
seq
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020843 external-priority patent/WO2023215384A2/en
Publication of JP2025514978A publication Critical patent/JP2025514978A/ja
Publication of JP2025514978A5 publication Critical patent/JP2025514978A5/ja
Pending legal-status Critical Current

Links

JP2024563648A 2022-05-04 2023-05-03 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用 Pending JP2025514978A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263364188P 2022-05-04 2022-05-04
US63/364,188 2022-05-04
US202263366447P 2022-06-15 2022-06-15
US63/366,447 2022-06-15
US202263366662P 2022-06-20 2022-06-20
US63/366,662 2022-06-20
US202263378987P 2022-10-10 2022-10-10
US63/378,987 2022-10-10
PCT/US2023/020843 WO2023215384A2 (en) 2022-05-04 2023-05-03 Use of myostatin inhibitor for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
JP2025514978A JP2025514978A (ja) 2025-05-13
JP2025514978A5 true JP2025514978A5 (enExample) 2026-05-11

Family

ID=86732326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563648A Pending JP2025514978A (ja) 2022-05-04 2023-05-03 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用

Country Status (20)

Country Link
US (1) US20250326827A1 (enExample)
EP (2) EP4518970B1 (enExample)
JP (1) JP2025514978A (enExample)
KR (1) KR20250021401A (enExample)
CN (1) CN119451696A (enExample)
AU (1) AU2023265846A1 (enExample)
CA (1) CA3251441A1 (enExample)
DK (1) DK4518970T3 (enExample)
ES (1) ES3072446T3 (enExample)
FI (1) FI4518970T3 (enExample)
HR (1) HRP20260506T1 (enExample)
IL (1) IL316463A (enExample)
LT (1) LT4518970T (enExample)
MX (1) MX2024013313A (enExample)
PL (1) PL4518970T3 (enExample)
PT (1) PT4518970T (enExample)
RS (1) RS68105B1 (enExample)
SI (1) SI4518970T1 (enExample)
SM (1) SMT202600209T1 (enExample)
WO (1) WO2023215384A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2026076383A1 (en) * 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
PL4218804T3 (pl) * 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
EP4232151B1 (en) 2020-10-26 2025-10-22 Scholar Rock, Inc. Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
CN117545842A (zh) 2021-01-29 2024-02-09 拜奥卡德联合股份公司 SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应

Similar Documents

Publication Publication Date Title
JP7723649B2 (ja) 抗プロ/潜在型ミオスタチン抗体およびその使用方法
JP2006512899A5 (enExample)
JP2009511480A5 (enExample)
JP2019523295A5 (enExample)
JP2012504955A5 (enExample)
JP2024175003A5 (enExample)
JP2011506483A5 (enExample)
JP2010516229A5 (enExample)
JP2011528902A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2006522830A5 (enExample)
JPWO2023026791A5 (enExample)
JP2018535650A5 (enExample)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2012504634A5 (enExample)
JP2021527640A5 (enExample)
JP7198757B2 (ja) ミオスタチン活性化の阻害により代謝疾患を処置するための方法
JP2010520290A5 (enExample)
JP2023515675A5 (enExample)
JP2024518536A5 (enExample)
JP2025509266A5 (enExample)
JP2023510199A5 (enExample)
JP2022531205A5 (enExample)
JP2022520107A5 (enExample)